Key Highlights

  • Syndax Pharmaceuticals (NASDAQ:SNDX) fell 14.02% pre-market after an IPF trial miss, with a Market Value of USD 1.48 billion and an RSI of 34.3, on 30,136 shares, on 30,136 shares, on 30,136 shares, on 30,136 shares.
  • MacroGenics (NASDAQ:MGNX) fell 7.80% pre-market despite USD 327 million of pro forma cash, with a market value of USD 237 million and an RSI of 45.6, on 1,238 shares, on 1,238 shares, on 1,238 shares.
  • Jaguar Health (NASDAQ:JAGX) fell 5.17% pre-market after a rare-disease pivot funded by a license, with a market value of USD 9 million and an RSI of 45.4, on 19,904 shares, on 19,904 shares, on 19,904 shares.
  • Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% pre-market after a late filing notice, with a market value of USD 8 million and an RSI of 53.7, on 16,007 shares, on 16,007 shares, on 16,007 shares.

Syndax Pharmaceuticals (NASDAQ:SNDX): IPF Miss Hits the Stock

Syndax Pharmaceuticals (NASDAQ:SNDX) fell 14.02% pre-market to a listed USD 16.55 on 30,136 shares, with a market Capitalization of USD 1.48 billion and an RSI of 34.3 labeled Down. Syndax fell 14.02% pre-market after saying its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis, which ends its plans to advance the drug in IPF. The company said the result does not affect ongoing trials of the same drug in other settings, and axatilimab is already approved and sold as Niktimvo for chronic graft-versus-host disease. Axatilimab did not slow lung function decline better than placebo, and secondary measures such as time to progression and quality of life showed no benefit. The stock closed at USD 16.55 on October 12 against a 52-week range of USD 12.99 to USD 25.59, with an average analyst target near USD 37.55, and short interest is about 24.28% of the float. Losing an IPF opportunity removes one growth leg, so the stock now depends on Niktimvo sales and other trials. By market value it ranks 1 of 4 in this group. What to watch next: Niktimvo sales and the remaining axatilimab trials. Futures were muted on Tuesday morning with JPMorgan, Wells Fargo, Goldman Sachs and Citigroup reporting before the bell, and JPMorgan's EPS of USD 5.57 missed a USD 5.90 forecast before the stock recovered.

MacroGenics (NASDAQ:MGNX): Cash Above Market Value

MacroGenics (NASDAQ:MGNX) fell 7.80% pre-market to a listed USD 3.72 on 1,238 shares, with a market capitalization of USD 237 million and an RSI of 45.6 labeled Mixed. MacroGenics reported its second-quarter 2026 results on August 13, with total Revenue of USD 32.8 million compared with USD 6.9 million a year earlier, helped by partner payments. In July it sold its Manufacturing operations to Bora Pharmaceuticals for USD 122.5 million, received USD 119.6 million in cash at closing and moved to a fully outsourced model with a workforce of about 140. Cash, cash equivalents and marketable securities were USD 173.3 million at June 30, 2026, or USD 327 million pro forma after proceeds from Bora, Sanofi and Gilead, with a runway through 2028. The pipeline includes MGC026, a B7-H3 antibody drug conjugate, MGC028, an ADAM9 conjugate with preliminary data planned for late 2026, lorigerlimab, a PD-1 by CTLA-4 antibody, and MGC030, whose IND was cleared ahead of schedule. Pro forma cash of USD 327 million is about 1.4 times the USD 237 million market value on the screen, simple arithmetic, which means the market is valuing the pipeline below the cash balance. Clinical-stage results are binary, partner payments are lumpy, and a market value below cash signals doubts about the pipeline. By market value it ranks 2 of 4 in this group. What to watch next: ESMO data, MGC028 results and the first MGC030 dosing. South Korea's Kospi fell 5.5% on memory valuation concerns and China competition, Nasdaq 100 futures were down about 0.5%, and S&P 500 third-quarter Earnings are expected to grow 30.6%.

Jaguar Health (NASDAQ:JAGX): Pipeline Pivot to Rare Disease

Jaguar Health (NASDAQ:JAGX) fell 5.17% pre-market to a listed USD 4.64 on 19,904 shares, with a market capitalization of USD 9 million and an RSI of 45.4 labeled Down. Jaguar Health received USD 16 million of non-dilutive cash in January 2026 under a royalty-free US license of Mytesi and Canalevia-CA1 to Future Pak, which directs those US revenues away from Jaguar. The company is now concentrating on crofelemer for rare intestinal failure diseases, including microvillus inclusion disease, with a presentation at ESPGHAN 2026 describing parenteral support reductions in pediatric patients. First-quarter net revenue rose 816% from a year earlier on the license, and Research and Development expense was USD 3.9 million in the quarter. The company expects the NDA clinical package for MVID by year-end and plans an NDA filing in the second quarter of 2027, and the license includes up to USD 20 million of milestones and other payments, with USD 3.0 million already received. The USD 9 million market value is about half of the USD 16 million upfront payment, simple arithmetic, which shows how little the market credits the pipeline. Revenue is small, funding needs are recurring and a Nasdaq listing risk was flagged in its annual filing, so dilution is likely. By market value it ranks 3 of 4 in this group. What to watch next: the MVID NDA package, Future Pak milestones and financing. Bank of America and Morgan Stanley report on Wednesday, September CPI data is due the same day, and the Fed meets on October 27 and 28.

Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS): Late 10-K, Second Phase 3

Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% pre-market to a listed USD 5.20 on 16,007 shares, with a market capitalization of USD 8 million and an RSI of 53.7 labeled Up. Apimeds Pharmaceuticals US is a clinical-stage company developing Apitox, a bee venom-based toxin given intradermally, which has been used in South Korea to treat osteoarthritis pain since 2003. It plans a second Phase 3 trial to meet FDA standards and intends to submit a BLA only after demonstrating therapeutic effect and extended safety. The notice added a late-filing designation to the ticker, and a Trading halt that began on April 2, 2026 remained in effect when the notice was filed. A September 29 current report concerned MindWave, a wholly owned subsidiary, and the six-month cure period for the 10-K runs to about October 17. The USD 8 million market value means the company needs outside capital to fund a Phase 3 trial. A looming cure deadline, delisting risk, a costly second Phase 3 trial and a tiny market value make dilution very likely. By market value it ranks 4 of 4 in this group. What to watch next: the 10-K filing, the exchange cure deadline and Phase 3 funding. Oil traded above USD 100 a barrel on Iran and Strait of Hormuz Supply risks, and the 10-year Treasury Yield touched about 5.35% last week.

Where Things Stand

Only Syndax has a same-day catalyst among the biotech decliners, while MacroGenics, Jaguar and Apimeds fell on thin Volume with verified filings in the background. Syndax Pharmaceuticals (NASDAQ:SNDX) fell 14.02% with a market value of USD 1.48 billion. MacroGenics (NASDAQ:MGNX) fell 7.80% with a market value of USD 237 million. Jaguar Health (NASDAQ:JAGX) fell 5.17% with a market value of USD 9 million. Apimeds Pharmaceuticals US (NYSEAMERICAN:APUS) fell 5.19% with a market value of USD 8 million. Pre-market moves on thin volume often reverse, so the balance of evidence favors waiting for the open and for filings. Direction remains unknown, and each name carries its own risks. Verify the latest filings before acting, and treat the figures as a snapshot.